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The purpose of this study is to evaluate the efficacy of subcutaneous iohexol
injection into the metatarsal region for thoracic duct lymphangiography in dogs
and to determine the minimal effective dose. For the experimental study, iohexol
injection was performed subcutaneously into the metatarsal region of 5 normal
beagle dogs at three different doses (0.5, 0.75, and 1.0 ml/kg) and the regions
were massaged gently. Computed tomography (CT) was performed 1, 3, 5, 7, 10,
15, and 20 minutes after iohexol injection. Subjective quality was assessed and
Hounsfield unit (HU) values were measured at the different regions of interest
(ROIs) (T1, T4, T8, T13, and L3). Contrast-enhanced thoracic duct was
visualized in all dogs at the doses of 0.75 and 1.0 ml/kg, and in two dogs also
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at 0.5 ml/kg, at 3, 5, and 7 minutes. The thoracic duct was progressively more
attenuated with increasing iohexol doses. The thoracic duct can be visualized by
subcutaneous iohexol injection into the metatarsal region in dogs, and the
minimal effective dose is 0.75 ml/kg. Subcutaneous injection of iohexol into the
metatarsal region is readily applicable and can be a viable alternative to
conventional thoracic duct lymphangiography.
……………………………………………………………………………………………………
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Chylothorax is the accumulation of chylous effusion in the pleural space, and it
causes tachypnea, dyspnea, cough, and lethargy in dogs.1The therapeutic options
include medical therapy and surgical intervention.2 Surgery can potentially
resolve chylothorax if the clinical signs have not improved after medical
treatment or when they are intolerable.3 Various surgical treatments have been
introduced, including thoracic duct ligation,4 cisterna chyli ablation,5
thoracicomentalization,6 and pericardiectomy.7 Among these, thoracic duct ligation
is the first choice,8 and many surgeons recommend preoperative and
postoperative lymphangiography for this intervention.3,7,9,10 In a previous study,
computed tomography (CT) lymphangiography was shown to allow thoracic duct
identification without the superimposition of anatomic structures that may hinder
its accurate evaluation in radiographic lymphangiography.10 Moreover, the authors
argued that CT lymphangiography would lead to an improvement in surgical
planning and thus to increased success rates.10
Various methods of CT lymphangiography have been introduced: direct
mesenteric lymphatic vessel injection of contrast medium during
laparotomy,11ultrasound-guided percutaneous injection into mesenteric
lymphnodes, popliteal lymph node injection,12,13 and subcutaneous injection into
the area surrounding the anus.8,14,15 The injection into mesenteric lymphatic
vessels is invasive, because it requires surgical intervention, thus increasing the
total surgical time, and extreme care should be used while manipulating the dog
to avoid compromising the implanted catheter.16 Other conventional protocols,
such as injection into the popliteal lymph node and mesenteric lymph node,
require significant procedural experience.8 In popliteal lymph node injection, many
dogs may not have, unexpectedly, a palpable popliteal lymph node, and it may
be difficult to identify one even with ultrasound guidance.16Subcutaneous
lymphangiography is simpler than the previous protocols, and the use of the
perianal region in this context was reported previously.8 However, the metatarsal
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region is considered to be easier to access and to carry a lower risk of infection
compared with perianal injection.15
Previous study suggested contrast enhancement of the peripheral lymphatic
channels could be achieved by subcutaneous injection into the metatarsal
region.17 We hypothesized that central lymphatic channels could be enhanced by
subcutaneous injection into the metatarsal region and the more detailed anatomic
structure could be identified by the procedure. The goal of the present study
was to evaluate the efficacy of subcutaneous iohexol injection into the
metatarsal region for thoracic duct lymphangiography with CT in dogs and to




All procedures and standards of animal care were approved by the Seoul
National University Institutional Animal Care and Use Committee
(SNU-181227-1). Five healthy beagle dogs, weighing 7.6–10.0 kg (mean: 8.6 kg)
were used in this study. The dogs were judged to be healthy based on physical
examination and hematologic and serum chemistry analysis. Monitoring of side
effects related to the injection of the contrast agent in the metatarsal region,
such as lameness, skin necrosis, and irritation, was performed for 2 months.
2. Anesthetic protocol
Food was withheld for 12–24 hours before the CT study. All dogs were
premedicated with 0.01 mg/kg acepromazine and anesthesia was induced with 2
mg/kg alfaxalone intravenously to the cephalic vein through a 22-gauge catheter
and maintained with isoflurane in 100% oxygen via an endotracheal tube. The
dogs were monitored for heart and respiratory rates.
3. CT metatarsal subcutaneous lymphangiography
Dogs were positioned in sternal recumbency on the CT table and the scan
direction was from cranial to caudal. The hair of the metatarsal region was
clipped, and the skin aseptically prepared with povidone and alcohol. Three
different doses (0.5 ml/kg, 0.75 ml/kg, and 1 ml/kg) of iohexol (Omnipaque 300;
GE Healthcare, Milwaukee, WI), warmed to body temperature, were administered
subcutaneously for 2 minutes into the dorsal metatarsal region, using a
22-gauge catheter. After injection of the contrast medium, the injection site was
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gently massaged for 1 minute, then CT images were obtained using a
64-detector row CT scanner (Aquillion 64, Toshiba, Tochigi, Japan) with the
following imaging conditions: tube voltage 120 kVp, tube current 150 mAs, slice
thickness 0.5 mm, 0.75 sec/rotation, and 1.0 helical pitch. CT scanning was
carried out 1, 3, 5, 7, 10, 15, and 20 minutes after contrast medium injection,
with respiration control performed manually with the reservoir bag of the
anesthetic machine. When the thoracic duct was not enhanced properly,
reinjection into the opposite metatarsal region with the same dose of iohexol
was performed. To rule out the influence of previously injected contrast medium,
reinjection was performed after confirming that all central lymphatic ducts were
not enhanced in the CT scan. CT lymphangiography was repeated at different
doses (0.5 ml/kg, 0.75 ml/kg, and 1.0 ml/kg) at 2-week intervals.
4. Evaluation of CT images
CT images were reconstructed at 1 mm and further 1 mm retro-reconstruction
was performed for three-dimensional (3D) reconstruction. CT images were
independently viewed by two experienced observers (Kitae Kim, Kyuyong
Kang), who independently and subjectively assessed the quality of the
enhancement using transverse plane, multi-planar, and 3D images. During the
examination, the degree of enhancement of the thoracic duct was subjectively
scored as none, low, marginal, moderate, or good. If the enhanced thoracic duct
was not visualized between T1 and L3, it was scored as “none.” When the
length of the thoracic duct with contrast enhancement in the T1–L3 range was
less than 25%, it was scored as “low,” “marginal” if between 25 and 50%,
“moderate” if between 50% and 75%, and “good” if above 75%. When both
observers evaluated the contrast enhancement of thoracic duct as “good,” it was
considered “well enhanced.”
The attenuation value of the thoracic duct and its branches was then measured
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using the transverse plane of CT images of five regions of interest (ROIs) (L3,
T13, T8, T4, and T1). These ROIs were selected based on previous studies of
normal anatomic features of the large lymphatic vessels in dogs.18,19The inner
margin of the thoracic duct was traced manually, and the attenuation value was
measured automatically.
5. Data analysis
All statistical analysis was performed with commercially available statistical
software (IBM SPSS statistics 25.0, IBM Corp, Armonk, NY). One-way ANOVA
and Tukey’s test were applied to test for differences in the attenuation values of
lymphatic vessels at each dose. P-values < 0.05 were considered statistically
significant. Intraobserver and interobserver reproducibility were evaluated using
the intraclass correlation coefficient (ICC). ICC values of 0.80 or above were
considered as indicating excellent agreement.20
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Results
Well-enhanced lymphatic vessels were identified at 3, 5, and 7 minutes in all
dogs subjected to injection of 0.75 ml/kg and 1 ml/kg iohexol (Figure 1).
Despite two attempts at contrast medium injection, using both metatarsal
regions, well-enhanced thoracic ducts were detected only in two dogs (Dog 2,
Dog 5) at the dose of 0.5 ml/kg at 3, 5, and 7 minutes (Figure 2).
With an injection dose of 1 ml/kg, peak lymphatic attenuation occurred at 5
minutes at T1 and T4 and at 3 minutes at T8, T13, and L3, while peak
enhancement was observed at 5 minutes, with exception of L3, for which it was
observed at 3 minutes (Figure 3). The thoracic duct was progressively more
attenuated in all dogs and all measured areas with increasing dose of contrast
medium at well enhanced time points (3, 5 , and 7 minutes) (Figure 3). The
attenuation values were statistically different between all doses (p < 0.05).
Agreement between the two observers regarding thoracic duct attenuation was
excellent (intraobserver 1: 0.996, intraobserver 2: 0.997, interobserver: 0.994).
Moreover, the thoracic duct was well-enhanced in three dogs (Dog 1, Dog 2,
and Dog 3) at 1 minute with a 1 ml/kg injection. In addition, in three dogs
(Dog 2, Dog 3, and Dog 4) a well-enhanced thoracic duct with the same dose
was identified also at 10 minutes, while contrast-enhanced thoracic duct
disappeared at 15 minutes in all dogs. At the 0.75 ml/kg dose, a
contrast-enhanced thoracic duct could not be visualized at 10 minutes in any of
the dogs.
In helical CT lymphangiography, the cisterna chyli, the dilated and bipartite
portion of the lymph channel, was identified at the L2 and L3 levels in all dogs.
It continues cranially along the right dorsal side of the aorta through the
diaphragm, then ventrally through the cranial mediastinum to the venous system
where it terminates. A description of the morphological variations of the thoracic
duct was possible in all dogs (Figure 4).
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All dogs tolerated the injection well. No changes in respiratory or heart rate
were observed after the injection. In the 2-week monitoring period for side
effects after CT lymphangiography, no adverse effects were detected.
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FIGURE 1. Maximum intensity projection (MIP) reconstruction CT images after
CT lymphangiography with subcutaneous injection of contrast medium into the
metatarsal region at the dose of 1 ml/kg. Images were obtained at 1, 3, 5, 7,
and 10 minutes after injection. At 3, 5, and 7 minutes after injection, a
well-enhanced thoracic duct and additional branches can be identified.
- 9 -
FIGURE 2 Transverse CT images at the level of T8 at the dose of 0.5 (A), 0.75 (B), 1.0 ml/kg (C), 5 minutes after injection.
The thoracic duct was not enhanced after injection of 0.5 ml/kg (A). The attenuation of the left branch of the thoracic duct
(arrows) was 381 HU and 614 HU (C).
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FIGURE 3 Time course (3, 5, and 7 minutes) of the mean HU value of the thoracic duct in serial transverse CT images of
five ROIs after injection of three different doses of iohexol into the subcutaneous metatarsal region (A: L3 level; B: T13 level;
C: T8 level; D: T4 level; E: T1 level). Statistically significant differences were observed between 0.5 ml/kg and 0.75 ml/kg and
between 0.75 ml/kg and 1.0 ml/kg at all measured levels (all p-values < 0.05). At the dose of 1 ml/kg, the peak enhancement
time was 3 minutes at the L3, T13 and T8 levels, and 5 minutes at the T4 and T1 levels. The HU values showed a
maximum at 5 minutes, except for the T1 level at the dose of 0.75 ml/kg, where the maximum occurred at 3 minutes. At the
dose of 0.5 ml/kg, a well-enhanced thoracic duct was identified only in two out of five dogs.
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FIGURE 4 Schematic drawing of the thoracic duct in five dogs. It was possible
to describe the whole thoracic duct and its branches and their variation using




In the present study, CT lymphangiography using subcutaneous iohexol
injection into the metatarsal region to delineate the thoracic duct was
successfully performed in all dogs at the doses of 0.75 and 1.0 ml/kg. Only two
dogs (Dog 2, Dog 5) showed well enhanced thoracic ducts with a 0.5 ml/kg
injection. Therefore, the minimal effective dose of iohexol to delineate the
thoracic duct can be considered to be 0.75 ml/kg. A dose of 1.0 ml/kg may be
required when the thoracic duct needs to be particularly evident, or when
delayed CT scanning is expected, since this dose resulted in a significant higher
attenuation and, in some cases, a longer enhancement time, than the 0.5 and
0.75 ml/kg doses used in all dogs.
Peak enhancement occurred earlier in the caudal than in the cranial portion of
the thoracic duct after injection of 0.75 and 1 ml/kg iohexol, due to the time
needed for enough iohexol to reach the cranial part of the thoracic duct. At 3
minutes, three regions (L3, T13, and T8) showed peak enhancement at the dose
of 1.0 ml/kg, but only one region (L3) at the dose of 0.75 ml/kg. Presumably,
more pressure was generated to fill the deep lymphatics at 1.0 ml/kg than 0.75
ml/kg, so that early detection of contrast enhancement was possible with the
injection of 1.0 ml/kg.
In a previous study, thoracic duct visualization was achieved by magnetic
resonance imaging (MRI) with intradermal injection of a macromolecular
magnetic resonance contrast agent into the metatarsal region.21 Another previous
report suggests that subcutaneous injection of the contrast medium(gadofosveset
premixed with human serum albumin) into the metatarsal region cannot result in
sufficient pressure to force the agent into the deep lymphatic system, including
the thoracic duct, in pigs, whereas intradermal injection of contrast medium
results in sufficient interstitial pressure to fill the central lymphatics.22 However,
- 13 -
in the present study, a well-enhanced thoracic duct was visualized by
subcutaneous injection of iohexol into the metatarsal region in dogs. In a
previous study, injection of 1-2ml of water-soluble iodinated contrast
medium(iopamidol) into the subcutaneous tissues overlying the pes in dogs at
the level of the metatarsals was performed, and contrast-enhanced peripheral
lymphatic vessels and regional lymph nodes were identified using radiography.17
In the present study, subcutaneous injection of contrast medium into the
metatarsal region resulted in sufficient pressure to force the agent into the deep
lymphatic system as long as the contrast medium volume was sufficient. The
maximum amount of contrast medium injected subcutaneously was determined
based on the maximum recommended dose compatible with the welfare of the
experimental animals(1ml/kgatonesite).23 The lymph flow velocity is influenced
by multiple factors, including posture, consciousness, respiration, and cardiac
cycle.24 Although anesthesia might interrupt the lymphatic flow, in this study the
thoracic duct was well enhanced.
Thoracic duct lymphangiography is recommended as a standard procedure to
observe thoracic duct branches before and after thoracic duct ligation, which is
the first choice of treatment for chylothorax in small animals. To achieve
successful thoracic duct ligation, the ligation site must be determined through an
accurate assessment of the thoracic duct.8,10,11Preoperative lymphangiography can
be used to assess the thoracic duct to detect hidden collateral lymphatic ducts
and reduce the relapse rate. Indeed, failure to ligate all collateral branches of the
thoracic duct is thought to be a common cause of operative failure in dogs.10
Postoperative lymphangiography can confirm the successful occlusion of all
thoracic duct branches so that the surgeon can be more confident that recurrent
chylothorax is not due to the failure to completely occlude the thoracic duct at
the time of surgery.3 The small sample size and the analysis of only three doses
of iohexol are the main limitations of the present study; however, it is likely
that a larger sample size or the number of doses tests will not make a
significant difference in regards to the availability of this technique and its
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minimum effective dose.
In conclusion, the thoracic duct can be visualized using a subcutaneous
injection of iohexol into the metatarsal region at a minimum effective dose of
0.75 ml/kg. This is a simple, reliable, and less invasive method that can be used
in dogs. Further studies involving more animals will be needed to confirm the
safety of this technique.
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국문 초록
개의 중족골 피하에 iohexl 주입을 통한 전산화단층촬영
흉관 조영술
본 연구의 목적은 개의 흉관 조영술을 위해서 중족골 피하에 iohexol 조영제의 주
입의 이용가능성을 평가하고, 그 최소 용량을 정립하고자 하는 것이다.
실험실적 연구를 위해서 세 가지의 다른 용량(0.5, 0.75, 1.0 ml/kg)의 iohexol 조영
제를 다섯 마리의 정상 비글견의 중족골 피하에 주입 후 부드럽게 마사지 하였다.
전산화단층촬영을 iohexol 조영제 주입 후 1, 3, 5, 7, 10, 15, 20분 이후에 실시하였
다. 주관적인 조영의 질적 평가를 진행하였으며, Hounsfield unit (HU) 값을 각각
다른 부위의 region of interest (ROIs) (T1, T4, T8, T13, and L3)에서 측정하였다.
그 결과, 조영제 주입 시간 기준으로 3, 5, 7분 후에 0.75 와 1.0 ml/kg의 용량을
주입한 모든 개체에서 조영 증강된 흉관이 확인되었으며, 0.5 ml/kg에서는 두 마리
의 개체에서 확인되었다. iohexol의 용량을 증가함에 따라, 흉관의 조영의 정도가
증가하였다. 결론적으로 개에서 중족골 피하에 iohexol 주입을 통해 흉관의 영상화
가 가능하였으며, 그 최소 용량은 0.75 ml/kg 였다.
중족골 피하로의 iohexol 주입은 쉽게 이용 가능하며, 기존의 흉관 조영술 시, 실
행 가능한 대안으로 고려된다.
……………………………………………………………………………………………………
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